🇺🇸 Rifaximin (XIFAXAN) in United States

16 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 16

Most-reported reactions

1. Vomiting — 3 reports (18.75%)
2. Abdominal Pain — 2 reports (12.5%)
3. Chills — 2 reports (12.5%)
4. Nausea — 2 reports (12.5%)
5. Pyrexia — 2 reports (12.5%)
6. Acute Kidney Injury — 1 report (6.25%)
7. Animal Bite — 1 report (6.25%)
8. Blister — 1 report (6.25%)
9. Bowel Movement Irregularity — 1 report (6.25%)
10. Cardiac Arrest — 1 report (6.25%)

Source database →

Frequently asked questions

Is Rifaximin (XIFAXAN) approved in United States?

Rifaximin (XIFAXAN) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Rifaximin (XIFAXAN) in United States?

University of California, San Francisco is the originator. The local marketing authorisation holder may differ — check the official source linked above.